MedTrace Logo

Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer

NCT05144542 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-04-15

No results posted yet for this study

Summary

This clinical trial investigates the effects of switching from smoking regular cigarettes to electronic cigarettes (e-cigarettes) among older adult smokers at high risk for lung cancer. E-cigarettes use heated vapor to deliver nicotine. Information gained from this trial may help inform regulators of the potential risks and benefits of switching smokers at high risk for lung cancer to electronic cigarettes. This research also may help inform the Food and Drug Administration (FDA) how best to regulate e-cigarettes with the goal of improving public health.

Conditions

  • Lung Carcinoma

Interventions

PROCEDURE

Participants will vape electronic cigarettes for 26 weeks.

Participants will vape electronic cigarettes for 26 weeks.

DRUG

Nicotine Replacement

Smoke usual brand of cigarettes

DRUG

Nicotine Replacement

Vape e-cigarettes

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Jason Robinson, PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-07
Primary Completion
2026-10-17
Completion
2026-10-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05144542 on ClinicalTrials.gov